Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.
2.

2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With Human Immunodeficiency Virus.

Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, Corbett AH, Foley K, Leonard K, Treisman GJ, Selwyn P.

Clin Infect Dis. 2017 Oct 30;65(10):1601-1606. doi: 10.1093/cid/cix848.

3.

2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.

Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, Corbett AH, Foley K, Leonard K, Treisman GJ, Selwyn P.

Clin Infect Dis. 2017 Oct 30;65(10):e1-e37. doi: 10.1093/cid/cix636. Review.

4.

Improving the asthma disparity gap with legal advocacy? A qualitative study of patient-identified challenges to improve social and environmental factors that contribute to poorly controlled asthma.

Harris DA, Mainardi A, Iyamu O, Rosenthal MS, Bruce RD, Pisani MA, Redlich CA.

J Asthma. 2018 Aug;55(8):924-932. doi: 10.1080/02770903.2017.1373393. Epub 2017 Oct 20.

PMID:
28872933
5.

Innovative Program Delivery and Determinants of Frequent Visitation to a Mobile Medical Clinic in an Urban Setting.

Gibson BA, Morano JP, Walton MR, Marcus R, Zelenev A, Bruce RD, Altice FL.

J Health Care Poor Underserved. 2017;28(2):643-662. doi: 10.1353/hpu.2017.0065.

PMID:
28529215
6.

New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.

Beckman AL, Bilinski A, Boyko R, Camp GM, Wall AT, Lim JK, Wang EA, Bruce RD, Gonsalves GS.

Health Aff (Millwood). 2016 Oct 1;35(10):1893-1901.

PMID:
27702964
7.

HIV testing at a community health center before and after implementing universal screening.

Kayingo G, Bruce RD.

JAAPA. 2016 Aug;29(8):45-6. doi: 10.1097/01.JAA.0000488696.73423.02.

PMID:
27467298
8.

Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.

Ogbuagu O, Friedland G, Bruce RD.

Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):721-31. doi: 10.1080/17425255.2016.1183644. Epub 2016 May 30. Review.

PMID:
27140427
9.

Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania.

Ubuguyu O, Tran OC, Bruce RD, Masao F, Nyandindi C, Sabuni N, McCurdy S, Mbwambo J, Lambdin BH.

Int J Drug Policy. 2016 Apr;30:74-81. doi: 10.1016/j.drugpo.2016.03.005. Epub 2016 Mar 11.

10.

"Can't you initiate me here?": Challenges to timely initiation on antiretroviral therapy among methadone clients in Dar es Salaam, Tanzania.

Saleem HT, Mushi D, Hassan S, Bruce RD, Cooke A, Mbwambo J, Lambdin BH.

Int J Drug Policy. 2016 Apr;30:59-65. doi: 10.1016/j.drugpo.2015.12.009. Epub 2015 Dec 19.

11.

Epidemiology of Drug Use and HIV-Related Risk Behaviors among People Who Inject Drugs in Mwanza, Tanzania.

Tan AX, Kapiga S, Khoshnood K, Bruce RD.

PLoS One. 2015 Dec 23;10(12):e0145578. doi: 10.1371/journal.pone.0145578. eCollection 2015.

12.

The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.

Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP.

Clin Infect Dis. 2016 Feb 1;62(3):298-304. doi: 10.1093/cid/civ894. Epub 2015 Nov 30.

13.

Novel Alleles of gon-2, a C. elegans Ortholog of Mammalian TRPM6 and TRPM7, Obtained by Genetic Reversion Screens.

Lambie EJ, Bruce RD 3rd, Zielich J, Yuen SN.

PLoS One. 2015 Nov 25;10(11):e0143445. doi: 10.1371/journal.pone.0143445. eCollection 2015.

14.

Service integration: opportunities to expand access to antiretroviral therapy for people who inject drugs in Tanzania.

Lambdin BH, Mbwambo JK, Josiah RM, Bruce RD.

J Int AIDS Soc. 2015 Jul 21;18:19936. doi: 10.7448/IAS.18.1.19936. eCollection 2015. No abstract available.

15.

Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M.

Antimicrob Agents Chemother. 2015 Sep;59(9):5503-10. doi: 10.1128/AAC.00478-15. Epub 2015 Jun 29.

16.

Implementation and Operational Research: Linkage to Care Among Methadone Clients Living With HIV in Dar es Salaam, Tanzania.

Tran OC, Bruce RD, Masao F, Ubuguyu O, Sabuni N, Mbwambo J, Lambdin BH.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):e43-8. doi: 10.1097/QAI.0000000000000582.

17.

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.

Hulskotte EG, Bruce RD, Feng HP, Webster LR, Xuan F, Lin WH, O'Mara E, Wagner JA, Butterton JR.

Eur J Clin Pharmacol. 2015 Mar;71(3):303-11. doi: 10.1007/s00228-014-1789-4. Epub 2015 Feb 11.

PMID:
25666027
18.

Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups.

Ogbuagu O, Bruce RD.

Curr HIV/AIDS Rep. 2014 Dec;11(4):505-12. doi: 10.1007/s11904-014-0238-4. Review.

PMID:
25342571
19.

Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model.

Morano JP, Zelenev A, Walton MR, Bruce RD, Altice FL.

Am J Public Health. 2014 Aug;104(8):1508-15. doi: 10.2105/AJPH.2014.301897. Epub 2014 Jun 12.

20.

Active case finding for tuberculosis among people who inject drugs on methadone treatment in Dar es Salaam, Tanzania.

Gupta A, Mbwambo J, Mteza I, Shenoi S, Lambdin B, Nyandindi C, Doula BI, Mfaume S, Bruce RD.

Int J Tuberc Lung Dis. 2014 Jul;18(7):793-8. doi: 10.5588/ijtld.13.0208.

21.

Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study.

Lambdin BH, Masao F, Chang O, Kaduri P, Mbwambo J, Magimba A, Sabuni N, Bruce RD.

Clin Infect Dis. 2014 Sep 1;59(5):735-42. doi: 10.1093/cid/ciu382. Epub 2014 May 22.

22.

The marketing of methadone: how an effective medication became unpopular.

Bruce RD.

Int J Drug Policy. 2013 Nov;24(6):e89-90. doi: 10.1016/j.drugpo.2013.10.006. Epub 2013 Oct 26. No abstract available.

PMID:
24246504
23.

Lessons from Tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment.

Bruce RD, Lambdin B, Chang O, Masao F, Mbwambo J, Mteza I, Nyandindi C, Zamudio-Haas S, Buma D, Dunbar MS, Kilonzo G.

Int J Drug Policy. 2014 Jan;25(1):22-5. doi: 10.1016/j.drugpo.2013.09.005. Epub 2013 Sep 19.

PMID:
24210295
24.

The reply.

Bruce RD, Beletsky L, Stancliff S, Bowman S.

Am J Med. 2013 Nov;126(11):e21-2. doi: 10.1016/j.amjmed.2013.07.020. No abstract available.

PMID:
24157295
25.

The reply.

Bruce RD, Beletsky L, Stancliff S.

Am J Med. 2013 Nov;126(11):e17. doi: 10.1016/j.amjmed.2013.08.003. No abstract available.

PMID:
24157293
26.

Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Pharmacogenomics J. 2014 Jun;14(3):303-8. doi: 10.1038/tpj.2013.30. Epub 2013 Oct 15.

27.

Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance.

Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH.

Antimicrob Agents Chemother. 2013 Dec;57(12):6154-7. doi: 10.1128/AAC.01229-13. Epub 2013 Sep 30.

28.

Effectiveness and feasibility study of routine HIV rapid testing in an urban methadone maintenance treatment program.

Seewald R, Bruce RD, Elam R, Tio R, Lorenz S, Friedmann P, Rabin D, Garger YB, Bonilla V Jr, Perlman DC.

Am J Drug Alcohol Abuse. 2013 Jul;39(4):247-51. doi: 10.3109/00952990.2013.798662.

29.

Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania.

Lambdin BH, Bruce RD, Chang O, Nyandindi C, Sabuni N, Zamudio-Haas S, McCurdy S, Masao F, Ivo Y, Msami A, Ubuguy O, Mbwambo J.

PLoS One. 2013 Jun 25;8(6):e67062. doi: 10.1371/journal.pone.0067062. Print 2013.

30.

Is it time for treatment as prevention among people who inject drugs?

Bruce RD.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):545-7. doi: 10.1097/QAI.0b013e31829f215e. No abstract available.

PMID:
23774878
31.

Latent tuberculosis infection: screening and treatment in an urban setting.

Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL.

J Community Health. 2013 Oct;38(5):941-50. doi: 10.1007/s10900-013-9704-y.

32.

Reducing the health consequences of opioid addiction in primary care.

Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD.

Am J Med. 2013 Jul;126(7):565-71. doi: 10.1016/j.amjmed.2012.11.031. Epub 2013 May 8. Review.

PMID:
23664112
33.

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH.

Expert Rev Clin Pharmacol. 2013 May;6(3):249-69. doi: 10.1586/ecp.13.18. Review.

34.

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Neuropsychopharmacology. 2013 Sep;38(10):2003-10. doi: 10.1038/npp.2013.99. Epub 2013 Apr 23. Erratum in: Neuropsychopharmacology. 2014 Mar;39(4):1039.

35.

The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.

Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):480-4. doi: 10.1097/QAI.0b013e3182961d31.

PMID:
23599011
36.

Evidence-based prevention interventions for people who use illicit drugs.

Kresina TF, Bruce RD, Mulvey KP.

Adv Prev Med. 2013;2013:360957. doi: 10.1155/2013/360957. Epub 2013 Mar 13. No abstract available.

37.

Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.

Qian F, Bolen CR, Jing C, Wang X, Zheng W, Zhao H, Fikrig E, Bruce RD, Kleinstein SH, Montgomery RR.

Clin Vaccine Immunol. 2013 Feb;20(2):146-55. doi: 10.1128/CVI.00530-12. Epub 2012 Dec 5.

38.

Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.

Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6. doi: 10.1016/j.drugalcdep.2012.08.002. Epub 2012 Aug 22.

39.

Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.

Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, Tawadrous M.

Drug Alcohol Depend. 2012 Nov 1;126(1-2):183-8. doi: 10.1016/j.drugalcdep.2012.05.009. Epub 2012 Jun 8.

PMID:
22682979
40.

Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence.

Schwarz R, Zelenev A, Bruce RD, Altice FL.

J Subst Abuse Treat. 2012 Dec;43(4):451-7. doi: 10.1016/j.jsat.2012.03.008. Epub 2012 Apr 24.

41.

Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.

Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL.

Am J Drug Alcohol Abuse. 2012 May;38(3):206-12. doi: 10.3109/00952990.2011.643975. Epub 2012 Jan 13.

42.

One stop shopping - bringing services to drug users.

Bruce RD.

Int J Drug Policy. 2012 Mar;23(2):104. doi: 10.1016/j.drugpo.2011.09.008. Epub 2011 Nov 16. No abstract available.

PMID:
22093675
43.

Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al.

Bruce RD.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e112; author reply e112-3. doi: 10.1097/QAI.0b013e31822c1d28. No abstract available.

PMID:
22033233
44.

Concerns about injectable naltrexone for opioid dependence.

Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD.

Lancet. 2011 Apr 30;377(9776):1468-70. doi: 10.1016/S0140-6736(10)62056-9. No abstract available.

PMID:
21529930
45.

Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH.

Am J Drug Alcohol Abuse. 2011 Jul;37(4):224-8. doi: 10.3109/00952990.2011.568081. Epub 2011 Mar 28.

PMID:
21438849
46.

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

47.

Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users.

Copenhaver MM, Lee IC, Margolin A, Bruce RD, Altice FL.

Subst Abus. 2011 Jan;32(1):16-26. doi: 10.1080/08897077.2011.540466.

48.

Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.

Saber-Tehrani AS, Bruce RD, Altice FL.

Am J Drug Alcohol Abuse. 2011 Jan;37(1):1-11. doi: 10.3109/00952990.2010.540279. Review.

PMID:
21247284
49.

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):511-4.

50.

Medical interventions for addictions in the primary care setting.

Bruce RD.

Top HIV Med. 2010 Feb-Mar;18(1):8-12. Review.

Supplemental Content

Loading ...
Support Center